1. Home
  2. STC vs MESO Comparison

STC vs MESO Comparison

Compare STC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STC
  • MESO
  • Stock Information
  • Founded
  • STC 1893
  • MESO 2004
  • Country
  • STC United States
  • MESO Australia
  • Employees
  • STC N/A
  • MESO N/A
  • Industry
  • STC Specialty Insurers
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • STC Finance
  • MESO Health Care
  • Exchange
  • STC Nasdaq
  • MESO Nasdaq
  • Market Cap
  • STC 2.1B
  • MESO 1.8B
  • IPO Year
  • STC N/A
  • MESO N/A
  • Fundamental
  • Price
  • STC $77.80
  • MESO $17.36
  • Analyst Decision
  • STC Buy
  • MESO Strong Buy
  • Analyst Count
  • STC 2
  • MESO 2
  • Target Price
  • STC $77.50
  • MESO $24.00
  • AVG Volume (30 Days)
  • STC 173.6K
  • MESO 177.3K
  • Earning Date
  • STC 10-22-2025
  • MESO 08-28-2025
  • Dividend Yield
  • STC 2.72%
  • MESO N/A
  • EPS Growth
  • STC 69.60
  • MESO N/A
  • EPS
  • STC 3.60
  • MESO N/A
  • Revenue
  • STC $2,796,513,000.00
  • MESO $17,198,000.00
  • Revenue This Year
  • STC $17.67
  • MESO $440.77
  • Revenue Next Year
  • STC $10.14
  • MESO $110.74
  • P/E Ratio
  • STC $21.42
  • MESO N/A
  • Revenue Growth
  • STC 16.09
  • MESO 191.39
  • 52 Week Low
  • STC $56.39
  • MESO $9.61
  • 52 Week High
  • STC $78.61
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • STC 67.91
  • MESO 62.39
  • Support Level
  • STC $70.86
  • MESO $14.32
  • Resistance Level
  • STC $78.61
  • MESO $15.61
  • Average True Range (ATR)
  • STC 2.32
  • MESO 0.57
  • MACD
  • STC 0.64
  • MESO 0.24
  • Stochastic Oscillator
  • STC 86.18
  • MESO 89.97

About STC Stewart Information Services Corporation

Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: